ACRS Aclaris Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACRS

Price (delayed)

$1.39

Market cap

$99.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$63.22M

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
ACRS's debt has plunged by 100% YoY
Aclaris Therapeutics's EPS has increased by 24% YoY and by 14% QoQ
Aclaris Therapeutics's quick ratio has surged by 66% QoQ but it has decreased by 32% YoY
Aclaris Therapeutics's gross margin has decreased by 29% YoY
ACRS's gross profit is down by 28% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aclaristx.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
71.26M
Market cap
$99.06M
Enterprise value
$63.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
3.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.03
Earnings
Revenue
$31.12M
EBIT
-$77.63M
EBITDA
-$76.72M
Free cash flow
-$73.68M
Per share
EPS
-$1.09
Free cash flow per share
-$1.04
Book value per share
$2
Revenue per share
$0.44
TBVPS
$2.45
Balance sheet
Total assets
$174.07M
Total liabilities
$32.05M
Debt
$0
Equity
$142.01M
Working capital
$115.26M
Liquidity
Debt to equity
0
Current ratio
6.74
Quick ratio
6.4
Net debt/EBITDA
0.47
Margins
EBITDA margin
-246.5%
Gross margin
42%
Net margin
-248.3%
Operating margin
-352.4%
Efficiency
Return on assets
-37.4%
Return on equity
-48.6%
Return on invested capital
-54.9%
Return on capital employed
-50.4%
Return on sales
-249.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
2.96%
1 week
5.3%
1 month
25.23%
1 year
-85.92%
YTD
32.38%
QTD
26.36%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$31.12M
Gross profit
$13.07M
Operating income
-$109.67M
Net income
-$77.26M
Gross margin
42%
Net margin
-248.3%
Aclaris Therapeutics's gross margin has decreased by 29% YoY
ACRS's gross profit is down by 28% YoY
The company's net income rose by 20% YoY and by 13% QoQ
ACRS's net margin is up by 20% YoY and by 12% from the previous quarter

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
3.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.03
Aclaris Therapeutics's EPS has increased by 24% YoY and by 14% QoQ
ACRS's P/B is 82% below its 5-year quarterly average of 3.7 and 68% below its last 4 quarters average of 2.1
ACRS's equity is down by 20% YoY and by 10% QoQ
ACRS's P/S is 95% below its 5-year quarterly average of 62.3 and 76% below its last 4 quarters average of 12.8

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has increased by 20% YoY and by 12% QoQ
The company's return on equity rose by 8% QoQ but it fell by 4.7% YoY
The ROA has increased by 7% from the previous quarter
Aclaris Therapeutics's return on invested capital has increased by 6% QoQ

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's quick ratio has surged by 66% QoQ but it has decreased by 32% YoY
ACRS's current ratio has surged by 62% since the previous quarter but it is down by 33% year-on-year
ACRS's debt is 100% less than its equity
ACRS's debt has plunged by 100% YoY
ACRS's equity is down by 20% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.